Phase 1 Completed N=96 Randomized Quadruple-blind Other

GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

Obesity

Source: ClinicalTrials.gov NCT04779697 ↗

Enrolled (actual)

Serious AEs

1.0%

Results posted

Feb 2026

Primary outcomePrimary: Change in Craving Score — -0.7; -0.3 score — p=< 0.001

Summary

To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Craving Score	-0.7; -0.3	< 0.001 sig
PRIMARY Change in Hunger Score	-0.5; -0.1	> 0.27
PRIMARY Change in Food Intake	-0.4; 0.4	< 0.043 sig
SECONDARY Change in Food Intake - Real-World	-485.7; -124.5	< 0.015 sig
SECONDARY Change in Stress Score	-2.8; -1.7	> 0.53

Eligibility Criteria

Inclusion Criteria

BMI ranging from 30-49.9 kg/m2
No significant medical problems, including diabetes
No history of HgbA1c 10% of total body weight during the prior 6 months
Taking any other anti-obesity medication
History of pancreatitis, medullary thyroid cancer, or MEN syndrome, or (6) women who are pregnant or lactating, or peri/postmenopausal

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04779697). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.